Yale School of Public Health
Dr. Anthony Bahinski is Chief Technology Officer at Vivodyne, where he leads the translation of Vivodyne’s automated platform for massively scalable safety and efficacy testing on lifelike lab-grown human tissues to pharmaceutical and regulatory partners. Prior to joining Vivodyne, he served as the Global Head of Safety Pharmacology at GlaxoSmithKline. At GlaxoSmithKline, his responsibilities were focused on coordinating a global strategy to investigate safety risks of drugs on the cardiovascular, respiratory, CNS, renal, and other specialized tissues, both in vitro and in vivo. Dr. Bahinski’s career spans academic research and large Pharma, with more than 20 years’ experience in the pharmaceutical industry. He served as Lead Senior Staff Scientist on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA and FDA collaborative efforts in development of organ chip systems. Dr. Bahinski has served on several advisory boards and is a current member of the Science Board of the US FDA, US EPA Board of Scientific Counselors (BOSC), and the Industrial Advisory Board for Dutch Research Council awarded SMART Organ on Chip (OoC) project. He is a member of the Editorial Board of the journals, Applied In Vitro Toxicology and Frontiers in Pharmacology of Ion Channels and Channelopathies. He has served on Peer Review Panels at the NIH, US EPA and NCI SBIR. Dr. Bahinski is author/co-author of over 40 publications including peer-reviewed articles and book chapters.
Sumitomo Dainippon Pharma Co., Ltd.
Environment and Climate Change Canada
Trinidad & Tobago Ministry of Health
Dr. Brown Jordan is from the Caribbean twin nation of Trinidad & Tobago (T&T). She was awarded a PhD in Veterinary Microbiology from the University of the West Indies, St. Augustine Campus in 2019, while her masters program at the London School of Hygiene and Tropical Medicine was in the field of Medical Microbiology. She was a past recipient of an Epigenesis Young Scientist Award for Animal Health in the Caribbean, a project initiative by the French Agricultural Research Centre for International Development (CIRAD). Her research areas of interest and background reside in laboratory diagnostics for both human and animal health pathogens of importance, with specific strengths in molecular biology and virology.
She has worked extensively with various governmental institutions in the area of laboratory strengthening due to her extensive knowledge in viral agents, emerging pathogens as well as modern laboratory and diagnostic sciences. Her knowledge and experiences have afforded her the opportunity to contribute more recently to the development of a new International Organization for Standards (ISO) standard document related to SARS-CoV-2 detection as well as to guide national establishment of molecular and antigen testing programs for SARS-CoV-2 in T&T.
Brown Jordan’s main propelling factors for being involved in research and scientific development, is her desire to see greater progress and strides towards the resolution of global challenges and going further towards implementation of the solutions, as evident by her pursuits. She is mother to and advocate for one special needs son and enjoys being a fashion creative when time is afforded.
US Food and Drug Administration
Dr. Suzanne Fitzpatrick is a board certified toxicologist here and in Europe and is an internationally recognized expert in alternative methods. She is the Senior Advisor for Toxicology at FDA/CFSAN. She is the FDA lead to ICCVAM and Tox 21 and chairs the FDA Alternative Methods Work Group. Dr. Fitzpatrick is the FDA representative to the International Regulatory Committee for the European Research Projects under ASPIS (Rik Hunter, ONTOX and Precision Tox) and she cochairs the EFSA and CFSAN Work Group on NAMS.
Public Health England
George Washington University
National Institute of Health Sciences, Japan
NIH National Heart, Lung, and Blood Institute
Wayne State University
Oregon State University
University of Taubaté / Planitox